LIAONING HE EYE HOSPITAL GROUP CO., LTD. Liaoning He Eye Hospital Group Co., LTD. Share Price
Equities
301103
CNE100005899
Healthcare Facilities & Services
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 22.48 CNY | -1.14% |
|
-2.85% | -25.02% |
| Sales 2022 | 955M 132M 10.37B | Sales 2023 | 1.19B 163M 12.87B | Capitalization | 4.74B 653M 51.45B |
|---|---|---|---|---|---|
| Net income 2022 | 33M 4.55M 358M | Net income 2023 | 63M 8.68M 684M | EV / Sales 2022 | 3.59 x |
| Net cash position 2022 | 1.55B 214M 16.88B | Net cash position 2023 | 1.33B 183M 14.44B | EV / Sales 2023 | 2.88 x |
| P/E ratio 2022 |
141
x | P/E ratio 2023 |
74.5
x | Employees | 3,455 |
| Yield 2022 |
3.17% | Yield 2023 |
2% | Free-Float | 31.7% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.14% | ||
| 1 week | -2.85% | ||
| Current month | -8.17% | ||
| 1 month | -11.04% | ||
| 3 months | -13.87% | ||
| 6 months | -25.24% | ||
| Current year | -25.02% |
1 week
22.35
23.17
1 month
21.9225.98
Current year
19.9731.25
1 year
19.9743.37
3 years
19.9748.99
5 years
19.9748.99
10 years
19.9748.99
| Managers | Title | Age | Since |
|---|---|---|---|
Wei He
CEO | Chief Executive Officer | 64 | 14/10/09 |
Ming Deng
DFI | Director of Finance/CFO | 55 | 31/10/15 |
Xiang Dong He
BRD | Director/Board Member | 61 | 14/10/09 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiang Dong He
BRD | Director/Board Member | 61 | 14/10/09 |
Wei He
CEO | Chief Executive Officer | 64 | 14/10/09 |
Ming Deng
DFI | Director of Finance/CFO | 55 | 31/10/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 19/06/24 | 22.48 | -1.14% | 597,330 |
| 18/06/24 | 22.74 | +0.40% | 419,320 |
| 17/06/24 | 22.65 | -1.09% | 563,000 |
| 14/06/24 | 22.9 | -0.91% | 667,107 |
| 13/06/24 | 23.11 | -0.13% | 660,583 |
End-of-day quote Shenzhen S.E., June 18, 2024
More quotes
Liaoning He Eye Hospital Group Co Ltd is a China-based company primarily engaged in the provision of ophthalmology specialist diagnosis and treatment services as well as optometry services for patients with eye diseases. The Company operates two segments. Diagnosis and Treatment Services segment provides cataract diagnosis and treatment services, refractive error diagnosis and treatment services, vitreoretinal diagnosis and treatment services, glaucoma diagnosis and treatment services, other diagnosis and treatment services, and non-surgical treatment. Optometry Services segment provides eye health assessment, optometry, and optical correction services for refractive errors, among others. The Company conducts its businesses in domestic market.
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.02% | 485M | |
| -29.52% | 14.28B | |
| +3.48% | 11.67B | |
| -7.21% | 11.16B | |
| +8.27% | 10.64B | |
| +27.94% | 8.6B | |
| -7.41% | 7.51B | |
| +8.01% | 6.84B | |
| +9.84% | 6.48B | |
| +16.35% | 4.43B |
- Stock Market
- Equities
- 301103 Stock
